Clinical Trial Update: Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting Phase 1/2 results for Elimusertib in relapsed or refractory solid tumors, including alveolar rhabdomyosarcoma and Ewing sarcoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Rhabdomyosarcoma
• Ewing Sarcoma
• Lymphoma
• Malignant Solid Neoplasm

Drugs mentioned

• Elimusertib (Elimusertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-23